Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
TD TDOC Teladoc Health, Inc. FY ended Feb 17, 2026 | $6.50 | $1.18B | $1.38B | $2.53B | $150.44M | -$200.32M | -5.70x | 0.47x | 4.18x |
GD GDRX GoodRx Holdings, Inc. FY ended Dec 31, 2025 | $3.53 | $1.20B | $1.70B | $796.85M | $113.48M | $30.44M | 39.22x | 1.51x | 9.00x |
CL CLOV CLOVER HEALTH INVESTMENTS, CORP. /DE FY ended Dec 31, 2025 | $4.23 | $2.22B | $2.09B | $1.92B | -$85.24M | -$85.55M | -9.61x | 1.15x | — |
RO ROIV Roivant Sciences Ltd. FY ended May 12, 2026 | $34.71 | $25.07B | $21.07B | $8.26M | -$131.66M | -$299.77M | -64.28x | 3035.33x | — |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 12.24x | 2/4 | $693.23M | — | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 759.61x | 4/4 | $1.78T | — | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -10.09x | 4/4 | -$1.30B | — | Peer averages are not economically meaningful for this method. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
TD TDOC Teladoc Health, Inc. FY ended Feb 17, 2026 | $6.50 | $1.18B | $1.38B | $2.53B | $150.44M | -$200.32M | -5.70x | 0.47x | 4.18x |
GD GDRX GoodRx Holdings, Inc. FY ended Dec 31, 2025 | $3.53 | $1.20B | $1.70B | $796.85M | $113.48M | $30.44M | 39.22x | 1.51x | 9.00x |
CL CLOV CLOVER HEALTH INVESTMENTS, CORP. /DE FY ended Dec 31, 2025 | $4.23 | $2.22B | $2.09B | $1.92B | -$85.24M | -$85.55M | -9.61x | 1.15x | — |
RO ROIV Roivant Sciences Ltd. FY ended May 12, 2026 | $34.71 | $25.07B | $21.07B | $8.26M | -$131.66M | -$299.77M | -64.28x | 3035.33x | — |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 12.24x | 2/4 | $693.23M | — | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 759.61x | 4/4 | $1.78T | — | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -10.09x | 4/4 | -$1.30B | — | Peer averages are not economically meaningful for this method. |
